Membership agreement between ChemBioFrance and Phare Bio
Exciting news! ChemBioFrance and the French National Chemical Library have officially signed a membership agreement with Phare Bio, a leading US techbio company advancing the use of generative AI in drug discovery.
By expanding access to novel chemical matter with therapeutic potential, their membership strengthens the global fight against antimicrobial resistance #AMR, one of today's most pressing health challenges.
We look forward to the groundbreaking discoveries that will emerge from this powerful combination of chemical diversity and AI-driven innovation.
ChemBioFrance
Offers « smart »chemical libraries with high potential for bioactivity, partnership with chemists for medicinal chemistry, drug screening services, tools for data analysis and data mining in chemical collections, ADME and toxicology services for the characterization and development of new biologically active molecules.
Chemical Library
A collection of more than 70.000 compounds and 15.000 extracts, originals, diverse and barely tested. Tailor-made sub-chemical libraries, adapted to your needs. Conditioning appropriate to broadband screenings. Simple procedures that maintain intellectual property. Skilled partnerships to develop hit-to-lead.
Chemoinformatics
Conception and analyzing of chemical library for screening. Analyzing of screening gross data. Virtual screening (similarity 2D and 3D, pharmaceutical library, docking). Biological profiling of molecules (target prediction). Calcul/ Prediction of physicochemical properties (e.g: solubility, logP)
Screening
A network of distributed platforms all over the country. A large panel of skills on many screening types. Assistance to devising, miniaturization and standardisation of tests.
ADME-Tox
Evaluation of pharmacokinetics properties of biologically active molecules, molecular properties (solubility, pKa, etc.) cellular tests (in vitro), in vivo tests (pharmacokinetics, BHE, etc.)
